30 closest matches · ranked by relevance
Hypertrophic Cardiomyopathy
Primary: Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. — -23; 31 Percentage change in fibrotic…
Cardiomyopathy, Hypertrophic Obstructive · Left Ventricular Outflow Tract Obstruction
Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg
Cardiomyopathy, Hypertrophic
Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506
Non-obstructive Hypertrophic Cardiomyopathy
Primary: Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) — 88.9; 90.5; 68.4 percentage of participants
Obstructive Hypertrophic Cardiomyopathy
Primary: Percentage of Participants Achieving A Clinical Response — 45; 22 Participants
Cardiomyopathy, Hypertrophic Obstructive
Primary: Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 — -60.6963 millimeters of mercury (mmHg)
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
Hypertrophic Cardiomyopathy
Primary: Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity — -0.06; -0.21 cm/sec…
Hypertrophic Cardiomyopathy
Primary: Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events — 13; 5 Participants
HOCM, Hypertrophic Obstructive Cardiomyopathy
Primary: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 — 10; 43 Participants — p=<0.0001
Cardiomyopathy, Hypertrophic
Primary: Change in Peak Oxygen Consumption (Peak VO2) — 1.35; 0.08 mL/kg/min
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Primary: Change From Baseline in pVO2 at Week 24 — 1.76; 0.02 mL/kg/min — p=<0.0001
Hypertrophic Cardiomyopathy (HCM)
Primary: Incidence of Adverse Events (AEs) — 10; 7; 11; 4 Participants
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
Obstructive Hypertrophic Cardiomyopathy
Primary: Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient — -51.05; 19.23 mmHg
Hypertrophic Cardiomyopathy
Primary: Recruitment as Assessed by Number of Participants Who Enrolled to the Study — 29; 13 Participants
Septal Myectomy
Primary: Septal Thickness Measured Before Cardiopulmonary Bypass — 22.9; 22.5 millimeters
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Primary: Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1 — 32.0 Percentage…
Genetic Predisposition · Genetic Hypertension
Primary: Left Ventricular Mass — 155.1680523; 129.5013331 gram
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
Obesity
Primary: Total Myocardial Oxygen Consumption (MVO2) — 1064; 1202; 947; 835 µmol/min
Heart Failure, Diastolic · Diastolic Heart Failure · Hypertension
Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio
Duchenne Muscular Dystrophy
Primary: 12-month Change in Myocardial Strain — 2.2; 1.0 percent change in heart dimension
Sickle Cell Disease
Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants
Duchenne Muscular Dystrophy · Cardiomyopathy
Primary: Number of Participants Experiencing Any of the Adjudicated Events — 0; 0; 0; 0 Participants
Heart Failure With Preserved Ejection Fraction · Hypertension
Primary: Difference in Home Systolic Blood Pressure — 130.7; 134.5 mm Hg — p=0.017
Obesity · Heart Failure, Diastolic · Metabolic Syndrome
Primary: Change From Baseline at 1 Year in Myocardial Lipid Content — -0.16; -0.18; -0.53; -0.19 %fat/water
Idiopathic Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months — 12; 10; 9 LVEF responders — p=0.685
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
Cardiac Catheterization · Blood Pressure · Heart Ventricles
Primary: Agreement Between SHAPE and Pressure Catheter Measurements — -0.8; -0.8 Correlation coefficient value